Erythematous-violaceous plaque in the frontal región
DOI:
https://doi.org/10.47196/dpa1jk22Keywords:
erythematoviolaceous plaque, frontal regiónAbstract
A 47-year-old male patient from Peru, a gardener by trade with no significant personal or family medical history, presented with an asymptomatic dermatosis on the forehead that had been evolving for two years. Physical examination of the forehead revealed erythematous-violaceous papules coalescing into a plaque with ill-defined, irregular borders; coalescent nodules partially involved the frontal hairline (Photo 1). The patient denied any history of local trauma, medication use, or infectious diseases in the months preceding the onset of the condition. Differential diagnoses considered included subcutaneous mycosis, papular mucinosis, sporotrichosis, phymatous rosacea, atypical mycobacterial infection, and folliculotropic mycosis fungoides. A 4 mm punch biopsy was performed for histopathological analysis, revealing an unremarkable epidermis. In the dermis, mild vascular dilation was observed, associated with an increased angiocentric chronic lymphocytic inflammatory infiltrate and abundant plasma cells; consequently, a Warthin-Starry stain was performed, yielding a negative result. No granulomatous reaction or deposits of amyloid or mucoid material were evident. PAS and Grocott stains were also negative (Photo 2). Additionally, mycological and bacteriological skin studies were requested—including cultures for atypical mycobacteria and common pathogens—but showed no microbial growth. General laboratory tests and serology (HBV, HCV, HIV) were also performed, with results falling within normal ranges. Due to issues regarding treatment accessibility, second-line therapy was initiated using minocycline (100 mg/day) and 1% ivermectin cream, alongside skin care measures, photoprotection, and avoidance of triggering factors. The patient showed clinical improvement and is currently being followed by our department, with no signs of recurrence or new lesions (Photo 3).
References
I. Hampton PJ, Berth-Jones J, Duarte Williamson CE, Hay R, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021. Br J Dermatol. 2021;185:725-735.
II. Geng RSQ, Bourkas AN, Mufti A, Sibbald RG. Rosacea: pathogenesis and therapeutic correlates. J Cutan Med Surg. 2024;28:178-189.
III. Farshchian M, Daveluy S. Rosacea. [Internet]. Treasure Island (FL): StatPearls; 2025.
IV. Chan JL, Soliman S, Miner AG, Hughes SM, et al. Metophyma: case report and review of a rare phyma variant. Dermatol Surg. 2011;37:867-869.
V. Veraldi S, Murgia G. Treatment of Metophyma with Isotretinoin. Acta Derm Venereol. 2024;104.
VI. Zhang H, Tang K, Wang Y, Fang R, et al. Rosacea treatment: review and update. Dermatol Ther. 2021;11:13-24.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor